1. Home
  2. /
  3. R&D Pipeline

Innovative technologies

Our dedicated team of scientists is committed to pioneering innovative technologies for the production of vaccines against infectious diseases. Our R&D approach harnesses the latest advancements in genetic engineering, protein conjugation, cell culture, and formulation.

Recombinant aP Family

Nucleic Acid Vaccines

Recombinant Viral Vaccines

Recombinant aP Family

Recombinant aP

Recombinant pertussis vaccine (aPgen)
R&D
100%
Pre-clinical
100%
Clinical
100%
.
100%
.
100%
Licensure
100%

Recombinant TdaP

Tetanus toxoid, reduced diphtheria toxoid and recombinant pertussis vaccine (TdaPgen)
R&D
100%
Pre-clinical
100%
Clinical
100%
.
100%
.
100%
Licensure
100%

Recombinant Tdap

Tetanus toxoid, reduced diphtheria toxoid, reduced recombinant pertussis vaccine (Tdapgen)
R&D
100%
Pre-clinical
100%
Clinical
100%
.
100%
.
100%
Licensure
100%

Recombinant ap

Reduced recombinant pertussis vaccine (apgen)
R&D
100%
Pre-clinical
100%
Clinical
100%
.
100%
.
100%
Licensure
50%

Pediatric DTaP

Diphtheria toxoid, tetanus toxoid, recombinant pertussis vaccine
R&D
100%
Pre-clinical
100%
Clinical
100%
.
100%
.
50%
Licensure
50%
pipeline

Nucleic Acid Vaccines

DNA COVID-19

COVID-19
R&D
100%
Pre-clinical
100%
Clinical
100%
.
50%
.
50%
Licensure
100%

DNA COVID-19 Variants

COVID-19
R&D
100%
Pre-clinical
100%
Clinical
50%
.
50%
.
50%
Licensure
100%

mRNA COVID-19

COVID-19
R&D
100%
Pre-clinical
100%
Clinical
100%
.
100%
.
50%
Licensure
100%

DNA Zika/Dengue

Zika/Dengue
R&D
100%
Pre-clinical
100%
Clinical
50%
.
50%
.
50%
Licensure
100%
pipeline

Recombinant Viral Vaccines

Chikungunya

Chikungunya
R&D
100%
Pre-clinical
50%
Clinical
50%
.
50%
.
50%
Licensure
50%

HBV

Hepatitis B
R&D
100%
Pre-clinical
50%
Clinical
50%
.
50%
.
50%
Licensure
50%

HPV

Human papillomavirus
R&D
100%
Pre-clinical
50%
Clinical
50%
.
50%
.
50%
Licensure
50%
pipeline